Page 36 - Relevant State News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Merus Announces Pricing of Public Offering of Common Shares Merus N.V.January 21, 2021 GMT UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an underwritten public offering of 4,848,485 common shares at a public offering price of $24.75 per share. T...

Merus Announces Pricing of Public Offering of Common Shares UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an underwritten public offering of 4,848,485 common shares at a public offering price of $24.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses...

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) ("Merus", "we" and "our"), a clinical-stage oncology company developing innovative, full-length

Merus N.V. Announces Proposed Public Offering of Common Shares January 19, 2021 16:18 ET | Source: Merus N.V. Merus N.V. Utrecht, NETHERLANDS UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced the launch of a proposed underwritten public offering of up to $60 million of its common shares. All of the common share...

Background In fully considering the different ways of meeting the minimum distribution requirements for REITs provided for in the JSE Listings Requirements (the “minimum distribution requirements”), Hyprop has taken extensive advice from its sponsor, attorneys and senior counsel, and has engaged openly with the JSE. This process commenced in August 2020 in advance of the publication of Hyprop’s notice of the annual general meeting (“AGM”) to be held in November 2020, which notice included, inter alia, Special Resolution 4 to enable Hyprop to settle the 2020 interim distribution by c...